Flotek (FTK) proposes sale of 87,187 shares worth $1.10M
Form 144 filed for Flotek Industries (FTK) reports a proposed sale of 87,187 common shares with an aggregate market value of $1,101,171.81 to be executed on the NYSE on 08/14/2025 through APEX CLEARING.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Form 144 filed for Flotek Industries (FTK) reports a proposed sale of 87,187 common shares with an aggregate market value of $1,101,171.81 to be executed on the NYSE on 08/14/2025 through APEX CLEARING.
The filing shows the shares were acquired by stock option exercises: 24,306 shares on 04/19/2021 and 62,881 shares on 12/05/2023. No securities were reported sold by the person in the past three months. The form includes the filer’s representation that they do not possess undisclosed material adverse information about the issuer. The filing does not disclose the name of the person for whose account the securities will be sold or the filer’s stated relationship to the issuer.
Insights
TL;DR Proposed sale is small relative to outstanding shares and is likely immaterial to company valuation.
The notice covers 87,187 shares with an aggregate market value of $1,101,171.81 against 29,860,000 shares outstanding. That quantity represents about 0.29% of outstanding common shares, indicating the transaction is modest in scale. The shares were obtained via stock option exercises in 2021 and 2023, and there are no reported sales in the prior three months. From a financial-impact perspective, the data in this form alone does not signal material dilution or a change in capital structure.
TL;DR Disclosure is procedurally complete but provides limited context on the seller’s identity or relationship to the issuer.
The filing specifies broker details (APEX CLEARING) and acquisition origins (stock option exercises) and includes the standard representation about absent undisclosed material adverse information. However, the form as provided does not supply the name of the person on whose account the sale is to be made or the filer’s relationship to the issuer, limiting governance transparency. Based solely on the form content, the filing appears routine rather than a governance red flag.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the broker handling the proposed FTK sale?
Does the filing disclose prior sales by the person in the past three months?
Does the Form 144 identify the person for whose account the securities will be sold or their relationship to Flotek?
AI-generated analysis. How Rhea-AI works. Not financial advice.